QQQ   293.72 (+0.12%)
AAPL   148.31 (+0.19%)
MSFT   254.69 (-0.18%)
META   120.44 (+1.98%)
GOOGL   100.99 (+0.00%)
AMZN   95.50 (-1.08%)
TSLA   194.70 (+0.00%)
NVDA   171.35 (+1.25%)
NIO   12.09 (-5.40%)
BABA   85.94 (-1.85%)
AMD   77.48 (-0.19%)
T   19.19 (-0.47%)
MU   55.49 (-3.75%)
CGC   3.93 (+8.56%)
F   14.08 (+1.29%)
GE   85.26 (-0.83%)
DIS   98.59 (+0.74%)
AMC   8.17 (+13.00%)
PYPL   78.53 (+0.15%)
PFE   51.08 (+1.90%)
NFLX   316.95 (+3.74%)
QQQ   293.72 (+0.12%)
AAPL   148.31 (+0.19%)
MSFT   254.69 (-0.18%)
META   120.44 (+1.98%)
GOOGL   100.99 (+0.00%)
AMZN   95.50 (-1.08%)
TSLA   194.70 (+0.00%)
NVDA   171.35 (+1.25%)
NIO   12.09 (-5.40%)
BABA   85.94 (-1.85%)
AMD   77.48 (-0.19%)
T   19.19 (-0.47%)
MU   55.49 (-3.75%)
CGC   3.93 (+8.56%)
F   14.08 (+1.29%)
GE   85.26 (-0.83%)
DIS   98.59 (+0.74%)
AMC   8.17 (+13.00%)
PYPL   78.53 (+0.15%)
PFE   51.08 (+1.90%)
NFLX   316.95 (+3.74%)
QQQ   293.72 (+0.12%)
AAPL   148.31 (+0.19%)
MSFT   254.69 (-0.18%)
META   120.44 (+1.98%)
GOOGL   100.99 (+0.00%)
AMZN   95.50 (-1.08%)
TSLA   194.70 (+0.00%)
NVDA   171.35 (+1.25%)
NIO   12.09 (-5.40%)
BABA   85.94 (-1.85%)
AMD   77.48 (-0.19%)
T   19.19 (-0.47%)
MU   55.49 (-3.75%)
CGC   3.93 (+8.56%)
F   14.08 (+1.29%)
GE   85.26 (-0.83%)
DIS   98.59 (+0.74%)
AMC   8.17 (+13.00%)
PYPL   78.53 (+0.15%)
PFE   51.08 (+1.90%)
NFLX   316.95 (+3.74%)
QQQ   293.72 (+0.12%)
AAPL   148.31 (+0.19%)
MSFT   254.69 (-0.18%)
META   120.44 (+1.98%)
GOOGL   100.99 (+0.00%)
AMZN   95.50 (-1.08%)
TSLA   194.70 (+0.00%)
NVDA   171.35 (+1.25%)
NIO   12.09 (-5.40%)
BABA   85.94 (-1.85%)
AMD   77.48 (-0.19%)
T   19.19 (-0.47%)
MU   55.49 (-3.75%)
CGC   3.93 (+8.56%)
F   14.08 (+1.29%)
GE   85.26 (-0.83%)
DIS   98.59 (+0.74%)
AMC   8.17 (+13.00%)
PYPL   78.53 (+0.15%)
PFE   51.08 (+1.90%)
NFLX   316.95 (+3.74%)
NASDAQ:BGNE

BeiGene - BGNE Price Target & Analyst Ratings

$194.57
+2.96 (+1.54%)
(As of 12/1/2022 12:00 AM ET)
Add
Compare
Today's Range
$188.32
$197.84
50-Day Range
$125.51
$207.71
52-Week Range
$118.18
$365.16
Volume
284,746 shs
Average Volume
283,458 shs
Market Capitalization
$20.20 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$239.50

BeiGene Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Buy
Based on 5 Analyst Ratings

Consensus Analyst Price Target

$239.50
23.09% Upside
High Prediction$296.00
Average Prediction$239.50
Low Prediction$210.00
TypeCurrent
12/1/21 to 12/1/22
1 Month Ago
11/1/21 to 11/1/22
3 Months Ago
9/2/21 to 9/2/22
1 Year Ago
12/1/20 to 12/1/21
Consensus Rating
Buy
Buy
Moderate Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
5 Buy rating(s)
5 Buy rating(s)
5 Buy rating(s)
7 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
1 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$239.50$249.00$299.25$356.88
Predicted Upside23.09% Upside53.33% Upside29.98% Upside12.63% Upside
Get BeiGene Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for BGNE and its competitors with MarketBeat's FREE daily newsletter.


BGNE Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

BGNE Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

BeiGene Stock vs. The Competition

TypeBeiGeneMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.66
2.48
Consensus RatingBuyBuyHold
Predicted Upside23.02% Upside573.48% Upside11.22% Upside
News Sentiment RatingNeutral News
Positive News
Neutral News
MarketBeat
Community Rating
Outperform Votes
521
70.22%
Underperform Votes
221
29.78%
Avg. Outperform Votes
164
66.40%
Avg. Underperform Votes
83
33.60%
Avg. Outperform Votes
853
68.13%
Avg. Underperform Votes
399
31.87%

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/15/2022Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$210.00+1.10%
11/10/2022Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$200.00 ➝ $213.00+13.39%
11/10/2022SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$200.00 ➝ $210.00+19.16%
10/13/2022Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight$290.00 ➝ $295.00+94.98%
8/9/2022JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight$296.00+51.11%
2/7/2022Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy
10/12/2021Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$431.00+18.56%
10/6/2021CLSA
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeUnderperform ➝ Buy
3/16/2021HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy$296.00 ➝ $385.00+18.32%
1/12/2021Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$185.00 ➝ $190.00-34.24%
12/8/2020LADENBURG THALM/SH SH
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Buy$278.00+23.04%
11/6/2020Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Naureen Quibria
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold
3/13/2020Macquarie
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeUnderperform ➝ Neutral
2/18/2020The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$197.30+15.32%
12/16/2019Piper Jaffray Companies
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Tyler Van Buren
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOverweight ➝ Neutral$165.00-4.65%
(Data available from 12/1/2017 forward. View 10+ years of historical ratings with our analyst ratings screener.)












BGNE Price Target - Frequently Asked Questions

What is BeiGene's consensus rating and price target?

According to the issued ratings of 5 analysts in the last year, the consensus rating for BeiGene stock is Buy based on the current 5 buy ratings for BGNE. The average twelve-month price prediction for BeiGene is $239.50 with a high price target of $296.00 and a low price target of $210.00. Learn more on BGNE's analyst rating history.

Do Wall Street analysts like BeiGene more than its competitors?

Analysts like BeiGene more than other Medical companies. The consensus rating score for BeiGene is 3.00 while the average consensus rating score for medical companies is 2.66. Learn more on how BGNE compares to other companies.

Do MarketBeat users like BeiGene more than its competitors?

MarketBeat users like BeiGene more than other Medical companies. 70.22% of MarketBeat users gave BeiGene an outperform vote while medical companies recieve an average of 66.26% outperform votes by MarketBeat users.

Is BeiGene being upgraded by Wall Street analysts?

Over the previous 90 days, BeiGene's stock had 2 upgrades by analysts.

Does BeiGene's stock price have much upside?

According to analysts, BeiGene's stock has a predicted upside of 35.32% based on their 12-month price targets.

What analysts cover BeiGene?

BeiGene has been rated by Cowen, Cowen, Guggenheim, Morgan Stanley, and SVB Leerink in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:BGNE) was last updated on 12/1/2022 by MarketBeat.com Staff